Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.
We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX). Because of life threatening plasma methotrexate (MTX) levels, carboxypeptidase G2 (CPDG2) was administered resulting in a dramatic decrease within 1 hr. The patient recovered from renal failure and no other side effects were observed. Homozygosity for the methylentetrahydrofolate reductase (MTHFR) C677T polymorphism diagnosed by molecular genetic analysis was the only explanation for this toxicity.
Turello
Rita
R
Pediatric Department, Hematology-Oncology Unit, University Hospital, 1011 Lausanne, Switzerland.
Rentsch
Katharina
K
Di Paolo
Ermindo
E
Popovic
Maja Beck
MB
D058186:Acute Kidney Injury / Q000139:chemically induced*; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects*; D002648:Child; D005260:Female; D006720:Homozygote; D006801:Humans; D016399:Lymphoma, T-Cell / Q000188:drug therapy; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects*; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics*; D011110:Polymorphism, Genetic
D000964:Antimetabolites, Antineoplastic; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D008727:Methotrexate